“My dream is that Italy, thanks to its infrastructure and location, can become the leading pharma manufacturing logistics hub for the Mediterranean region, joining northern Africa with the wider MENA region and with Europe”
Il Presidente ASSORAM Pierluigi Petrone ha rilasciato un’interessante intervista alla rivista online Pharma Boardroom. Nel corso della chiacchierata con il giornalista, Petrone ripercorre i temi core della sua esperienza come Presidente dell’Associazione e le sue speranze per il futuro della health supply chain italiana.
Di seguito un estratto dell’articolo, che puoi leggere cliccando qui.
What are the top items on your priority list as president of ASSORAM?
I would like to continue to see investment flows returning towards Italy, including for API and other pharmaceutical manufacturing that has tended to be outsourced to India and China in recent years. The first part of the pandemic showed the folly of this system.
My dream is that Italy, thanks to its infrastructure and location, can become the leading pharma manufacturing logistics hub for the Mediterranean region, joining northern Africa with the wider MENA region and with Europe. Power is nothing without control and, if a country is able to manufacture high value products but not distribute them in real time, it misses an opportunity to create value. Italy is a strong manufacturing country but can also be an even stronger logistics player. I really hope that the government of Mr Draghi, especially given his strong understanding of economic flows, can capitalise on the opportunities in this space.
Another big challenge for ASSORAM’s members is the price of energy and raw materials. Our members must maintain a temperature control for 24 hours a day, 365 days a year. They are also obliged to distribute products not with specialised temperature-controlled trucks, not only for the cold chain, but also for the ambience. I have made numerous pleas to the government about the costs involved in distribution of essential products to hospitals; prices are negotiated between AIFA and the pharma company by law and cannot subsequently be increased, making the margins incredibly tight and threatening the sustainability of the system.
Leggi l’intero articolo cliccando qui